Profusa, Inc. (NASDAQ:PFSA) Short Interest Update

Profusa, Inc. (NASDAQ:PFSA) was the target of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 53,192 shares, a decrease of 77.4% from the June 30th total of 234,995 shares. Currently, 28.8% of the shares of the stock are sold short. Based on an average trading volume of 282,122 shares, the short-interest ratio is currently 0.2 days.

Analysts Set New Price Targets

PFSA has been the subject of several research analyst reports. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Profusa Stock Performance

NASDAQ:PFSA traded down $0.05 on Friday, hitting $1.71. 25,686 shares of the stock were exchanged, compared to its average volume of 208,788. The stock has a market capitalization of $324,900.00, a price-to-earnings ratio of -0.00 and a beta of 0.46. Profusa has a 52 week low of $1.60 and a 52 week high of $4,162.50. The company’s 50-day moving average price is $5.12 and its 200 day moving average price is $44.19.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.